European Nuclear Medicine / Radiopharmaceuticals Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to  - MarketsandMarkets

European Nuclear Medicine / Radiopharmaceuticals Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to

European Nuclear Medicine / Radiopharmaceuticals Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to  - MarketsandMarkets
European Nuclear Medicine / Radiopharmaceuticals Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to
Published Apr 08, 2013
303 pages — Published Apr 08, 2013
Price US$ 4,650.00  |  Buy this Report Now

About This Report

  
Abstract:



Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation, used in the nuclear imaging field to diagnose and treat diseases. The European radioisotopes market was valued at $1.1 billion in 2012 and is poised to reach $1.6 billion in 2017 at a CAGR of 6.8%.

The radiopharmaceuticals market is broadly classified into two segments, namely, diagnostic and therapeutic; the former dominated with about 83% share in 2012. Radioisotopes in the diagnostic market are categorized as SPECT and PET. Technetium 99m (Tc-99m) dominated the SPECT radioisotope market in 2012, followed by Thallium-201(Tl-201), Gallium-67 (Ga-67) and Iodine-123 (I-123). SPECT is majorly used in cardiology related diagnosis; it is poised to grow at a CAGR of 7.0% from 2012 to 2017. The PET radioisotopes market is dominated by Fluoride-18 (F-18), followed by Rubidium-82 (Rb-82).

Segments in the therapeutic market are beta emitters, brachytherapy isotopes, and alpha emitters. Quantitative information about alpha emitters is not arrived at, as they have not been commercialized; recent clinical studies have, however, showcased immense potential of alpha isotopes in therapies. Beta emitters contribute the highest to the therapy market, dominated by Iodine-131(I-131), which is poised to grow at a CAGR of 3.9% from 2012 to 2017. European market is driven by its applications for thyroid cancer, hyperthyroidism, and non-Hodgkin's lymphoma. Significant isotopes in the brachytherapy market are Cesium-131 (Cs-131), Iodine-125 (I-125), Palladium-103 (Pd-103), and Iridium-192 (Ir-192). German is the major market for brachytherapy in terms of market share, followed by France. However, this market is showing slow growth due to reimbursement issues.

European stable isotopes market is dominated by Deuterium (D2), Oxygen-18 (O-18), Carbon-13 (C-13), and Nitrogen-15 (N-15). Research, pharmaceuticals, diagnostic and therapy, and industries are major applications. The European stable isotopes market was estimated at $24.7 million in 2012 and expected to reach $37.7 million by 2017 at a CAGR of 8.8%.

Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are boosting up the European nuclear medicines market. Upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential in the clinical diagnosis and therapeutic applications while the shutdown of NRU in 2016 and OSIRIS in France by 2018 seems to be the major threat for the manufacturers.

Germany is the largest consumer market for radiopharmaceuticals in the Europe. There are only 5 major reactors in the world and the rest of the countries are completely depend on the productions form those reactors and a few countries such as Poland, Australia, Argentina, and South Africa have started producing Mo-99 at their own reactors.

Major players in the radiopharmaceuticals market are Covidien, Plc (Ireland), GE Healthcare (U.K.), IBA Group (Belgium), Lantheus Medical Imaging, Inc. (U.S.), Nordion, Inc. (Canada), and Siemens Healthcare (PETNET) (Germany). The stable isotopes market was led by two players - Cambridge Isotope Laboratories (CIL) (U.S.), and Sigma Aldrich (U.S.) - in 2012; they jointly contributed more than 50% to the European revenue.

Scope of the Report

The radioisotope and stable isotope markets have been segmented according to the type of isotope, and applications. Both of these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by country (Germany, France, Italy, Spain, U.K., Russia, and Rest of Europe) to provide in-depth information on the European scenar

  
Source:
Document ID
PH 1867
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

Title
Table Of Contents

1 Introduction (Page No. - 25)
1.1 Key Take-Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size
1.5.2 Market Share
1.5.3 Key Data Points From Secondary Sources
1.5.4 Key Data Points From Primary Sources
1.5.5 Assumptions

2 Executive Summary (Page No. - 32)

3 Market Overview (Page No. - 37)
3.1 Introduction
3.2 Definition Of Radiopharmaceuticals
3.3 Evolution
3.4 Market Segmentation
3.4.1 Radiopharmaceuticals
3.4.2 Stable Isotopes
3.5 Market Dynamics
3.5.1 Drivers
3.5.1.1 Increasing Incidence Of Cancer And Cardiac Ailments Boosts The Demand For Radiopharmaceuticals
3.5.1.2 Increasing Use Of Spect And Pet Scans Results In Rise Of Radiopharmaceutical Usage
3.5.1.3 Rising Awareness Of Radiopharmaceuticals To Spur Growth
3.5.1.4 Ready Availability Of Radiopharmaceuticals From Cyclotrons To Goad The Growth
3.5.2 Restraints
3.5.2.1 Shorter Half-Life Of Radiopharmaceuticals Restricts The Usage
3.5.2.2 High Capital To Limit The Buying Of Scanners
3.5.2.3 Stringent Regulatory Guidelines And Gmp To Negatively Impact Growth
3.5.2.4 Competition From Conventional Diagnostic Procedures
3.5.3 Opportunities
3.5.3.1 Potential Radioisotopes In The Pipeline
3.5.3.2 Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
3.5.3.3 Alternative Diagnostic Radiopharmaceutical Solutions
3.5.3.4 Cyclotron Based Production
3.5.3.5 Neurological Applications
3.5.4 Threat
3.5.4.1 Shutdown Of Nuclear Reactors To Impact Production Of Radioisotopes
3.6 Winning Imperatives
3.6.1 Investments On New Radioisotopes And Novel Applications
3.6.2 Shift Towards Leu-Based Mo-99 Production
3.7 Burning Issues
3.7.1 High Cost Of Pet Cameras
3.7.2 Shortage In Supply Of Technetium-99m
3.8 Regulatory Affairs
3.8.1 Germany
3.8.1.1 German Medicinal Products Act (AMG)
3.8.1.2 Amendments To The German Medicinal Products Act (AMG)
3.8.2 France
3.8.2.1 Agence Française De La Securité Sanitaire Des Produits De La Santé (AFSSAPS)
3.8.3 U.K.
3.8.3.1 The Medicines And Healthcare Products Regulatory Agency (MHRA)
3.8.4 Spain
3.8.5 Italy
3.8.5.1 The Italian Pharmaceutical Agency (AIFA)
3.8.6 Russia
3.8.6.1 The Federal Law
3.9 Market Share Analysis
3.9.1 European Radiopharmaceuticals Market
3.9.1.1 Germany
3.9.1.2 France
3.9.1.3 Italy
3.9.1.4 Spain
3.9.1.5 U.K.
3.9.1.6 Switzerland
3.9.1.7 Russia
3.9.2 Enriched Stable Isotope Market

4 European Radiopharmaceuticals Market, By Isotope (Page No. - 65)
4.1 Introduction
4.2 Diagnostic Market
4.2.1 Opportunity Matrix
4.2.2 Single-Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals
4.2.2.1 Technetium-99m (Tc-99m)
4.2.2.1.1 Tc-99m To Decide Growth Trend Of Spect Radioisotopes
4.2.2.1.2 Factors Affecting Technetium-99m Market
4.2.2.1.2.1 Technetium Can Combine With 31 Different Carrier Molecules
4.2.2.1.2.2 Lack Of Availability Of Technetium
4.2.2.2 Thallium-201 (Tl-201)
4.2.2.2.1 Tl-201 Is A Potential Substitute For Tc-99m
4.2.2.3

Table Of Contents

MarketsandMarkets—Worldwide, market research reports primarily sold for numbers, market segmentation and competitive landscape, within the business leaders.

About the Author


Cite this Report

  
MLA:
MarketsandMarkets. "European Nuclear Medicine / Radiopharmaceuticals Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to " Apr 08, 2013. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/MarketsandMarkets/European-Nuclear-Medicine-Radiopharmaceuticals-Market-SPECT-PET-Radioisotopes-Technetium-F-18-Beta-Alpha-Radiation-Therapy-I131-Y-90-Applications-Cancer-Oncology-Cardiac-Stable-Isotopes-Deuterium-C-13-Global-Trends-Forecast-to-2144-96>
  
APA:
MarketsandMarkets. (2013). European Nuclear Medicine / Radiopharmaceuticals Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to Apr 08, 2013. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/MarketsandMarkets/European-Nuclear-Medicine-Radiopharmaceuticals-Market-SPECT-PET-Radioisotopes-Technetium-F-18-Beta-Alpha-Radiation-Therapy-I131-Y-90-Applications-Cancer-Oncology-Cardiac-Stable-Isotopes-Deuterium-C-13-Global-Trends-Forecast-to-2144-96>
  
US$ 4,650.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.